Front Runners: VBI Vaccines Inc (VBIV), Vitae Pharmaceuticals (VTAE), CyberArk Software (CYBR), Vapor Corp. (VPCO), Regulus Therapeutics (RGLS)

VBI Vaccines Inc (VBIV) is trading at an unusually high volume Monday with 61,251 shares changing hands. The thinly traded stock is up more than 24% in mid-day trading and trading at nearly 3x its 3-month average volume. We are not seeing any news to account for the move.

In the past 52 weeks, shares of Cambridge, Massachusetts-based biopharmaceutical company have traded between a low of $1.90 and a high of $7.45 with the 50-day MA and 200-day MA located at $2.87 and $4.14 levels, respectively. Additionally, shares have a Relative Strength Index (RSI) and MACD indicator of 48.69 and -0.11, respectively.

VBIV currently prints a one year loss of about 63.27% and a year-to-date loss of around 60.00%.

Vitae Pharmaceuticals, Inc. (VTAE) ) gained 27% to $11.59 in mid-day trading today. Approximately 480K shares have already changed hands, compared to the stock’s average daily volume of 278,543 shares. Just like VBIV, we are not seeing any catalysts to account for the upside.

Vitae Pharmaceuticals is currently valued at $199.77M. The name has a median Wall Street price target of $14.50 with a high target of $21.00.

CyberArk Software Ltd (CYBR) is a solid mover this session with its shares spiking nearly 11% on the day. The name continues to show strength Monday following a number of catalysts, including multiple coverage initiations and expiration of lock-up period.

Cyber-Ark shares are currently priced at 173.24x this year’s forecasted earnings compared to the industry’s 4.51x earnings multiple. Ticker has a PEG and forward P/E ratio of 144.96 and 666.45, respectively. Price/Sales for the same period is 11.82 while EPS is $0.19. Currently there are 3 analysts that rate CYBR a ‘Buy’, while 3 rate it a ‘Hold’. No analyst rates it a ‘Sell’. CYBR has a median Wall Street price target of $33.00 with a high target of $38.00.

Shares of Petach Tikva, Israel-based company trade between a low of $22.12 and a high of $35.88 and are now at $33.26.

Vapor Corp. (VPCO) is trading at unusually high volume Monday with 3.7 million shares changing hands. It is currently at 10x its average daily volume and trading up $0.72, or 43.64%, at $2.37 as of 2:28 p.m. ET.

Vapor Corp. has a forward PE of 11.75 and price-to-sales ratio of 1.12. EPS is ($0.12). The company has a market cap of $39.23M and is part of the consumer goods sector and cigarettes industry. Shares are down 64.89% year-over-year and 81.97% year-to-date.

Regulus Therapeutics Inc (RGLS) shares soared anew on Monday following the company’s announcement of positive results from its Hepatitis C Study on October 22. The move comes on solid volume too with the issue trading 8M shares compared to the average volume of 671,167.

RGLS shares have advanced 146.87% in the last 4 weeks and advanced 178.17% in the past three months. Over the past 5 trading sessions the stock has gained 161.39%. Shares of Regulus Therapeutics Inc. are up 134.51% this year.

The San Diego-based company, which is currently valued at $805.44M, has a median Wall Street price target of $18.00 with a high target of $19.00. RGLS is up 142.72% year-over-year.

Be the first to comment

Leave a Reply

Your email address will not be published.


*